$AGMB

$8.40 -$0.17 (1.98%) Close

$AGMB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 34.2M shares outstanding

Who owns AGMB?

By type of holder

Institutions 76.0% Insiders 0.3% Everyone else 23.8%

Concentration Top 10 holders own 77.9%

EQT Fund Management S.a r.l. 15.1% · LSP 7 Cooperatieve U.A. 15.1%

Institutional ownership

76.0%

+7.6 pts vs last qtr

Institutional holders

+2 vs last qtr

Net shares bought

+2.6M

by institutions in Q2 2026

New / sold out

9 / 7

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Redmile Group, LLC +2.6M
Nantahala Capital Management, LLC +368.2K

Biggest sellers in Q2 2026

LMR Partners LLP SOLD OUT −300.0K
Seven Grand Managers, LLC −152.4K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Agomab Therapeutics NV in the last 12 months.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for Agomab Therapeutics NV.

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years0% Under 1 year100%

Quarterly turnover

8.9%

of institutional shares changed hands

Top 10 managers, median time held

1 quarter

Super Investors

Investment managers reporting AGMB on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
EF EQT Fund Management S.a r.l.	5.1M	15.05%	Unchanged	Q1 '26	7.7%
Shares held by quarter Peak holding5.1M (Q1'26) Change over 8 quarters+5.1M Share of the company15.050% EQT Fund Management S.a r.l.'s full portfolio →
S Sanofi	2.8M	8.15%	Unchanged	Q1 '26	6.8%
Shares held by quarter Peak holding2.8M (Q1'26) Change over 8 quarters+2.8M Share of the company8.150% Sanofi's full portfolio →

EQT Fund Management S.a r.l.

5.1M

% of company

15.05%

Change vs last qtr

Unchanged

Held since

Q1 '26

Sanofi

2.8M

% of company

8.15%

Change vs last qtr

Unchanged

Held since

Q1 '26

28 more super investors behind a free account

See every manager holding Agomab Therapeutics NV, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting AGMB on Form N-PORT; together they hold 9.6% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FH Federated Hermes Kaufmann Fund Federated Hermes Equity Funds	$12.6M	981.2K	2.87%	0.26%	July 31, 2026
FH Federated Hermes Kaufmann Small Cap Fund Federated Hermes Equity Funds	$7.92M	615.7K	1.80%	0.28%	July 31, 2026

Federated Hermes Kaufmann Fund

Federated Hermes Equity Funds

Position value

$12.6M

% of company

2.87%

% of the fund

0.26%

As of

July 31, 2026

Federated Hermes Kaufmann Small Cap Fund

Federated Hermes Equity Funds

Position value

$7.92M

% of company

1.80%

% of the fund

0.28%

As of

July 31, 2026

11 more funds behind a free account

See every fund holding Agomab Therapeutics NV and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
L7 LSP 7 Cooperatieve U.A. 5%+ holder 13D · 10.6%	5.1M	15.05%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company15.050% Disclosed stake13D · 10.6% View the 13D/G filing →
KT Knotnerus Tim Jasper Insider	56.2K	0.16%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.160% Knotnerus Tim Jasper's insider activity →

LSP 7 Cooperatieve U.A.

5%+ holder13D · 10.6%

5.1M

% of company

15.05%

Change vs last qtr

—

Held since

—

Knotnerus Tim Jasper

Insider

56.2K

% of company

0.16%

Change vs last qtr

—

Held since

—

2 more holders behind a free account

See every insider and 5%+ holder of Agomab Therapeutics NV.

Comments